GR1803 Injection in Patients With RRMM
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06952075
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma
Phase 2
Recruiting
- Conditions
- Asthma
- Interventions
- Other: PlaceboDrug: GR1802 injection
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT06642961
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 582
- Registration Number
- NCT06635798
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Drug: GR1803 injection
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT06566547
- Locations
- 🇨🇳
he First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps
Phase 3
Not yet recruiting
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 228
- Registration Number
- NCT06516302
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
Phase 2
Active, not recruiting
- Conditions
- Allergic Rhinitis
- Interventions
- Biological: GR1802 injectionBiological: Placebo
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06315426
- Locations
- 🇨🇳
Hebei Petro China Central Hospital, Langfang, Hebei, China
🇨🇳Central Hospital of Qinghe County, Xingtai, Hebei, China
🇨🇳Zhengzhou Central Hospital, Zhengzhou, Henan, China
A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult
Phase 1
Recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: GR2102 injectionBiological: placebo
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 132
- Registration Number
- NCT06313697
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults
Phase 1
Completed
- Conditions
- Tetanus
- Interventions
- Biological: GR2001Biological: PlaceboBiological: HTIGBiological: Tetanus Toxoid
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 202
- Registration Number
- NCT06302374
- Locations
- 🇨🇳
Huashan Hospital affiliated of Fudan University, Shanghai, Shanghai, China
Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis
Phase 3
Not yet recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- Biological: placeboBiological: GR1802 injection
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT06216392
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, Shanghai, China
A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis.
Phase 1
Not yet recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- Biological: GR2002 injection
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06175143
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath